Barrington Research Issues Positive Forecast for HealthEquity (NASDAQ:HQY) Stock Price

HealthEquity (NASDAQ:HQY) had its price target boosted by equities research analysts at Barrington Research from $105.00 to $120.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Barrington Research’s price objective would suggest a potential upside of 18.18% from the company’s current price.

Several other equities research analysts also recently weighed in on HQY. BTIG Research upped their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. The Goldman Sachs Group began coverage on shares of HealthEquity in a report on Friday, November 15th. They issued a “neutral” rating and a $108.00 price objective for the company. JMP Securities reissued a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Bank of America increased their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.38.

HealthEquity Price Performance

Shares of HQY opened at $101.54 on Monday. HealthEquity has a 12 month low of $62.10 and a 12 month high of $105.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The stock has a fifty day moving average price of $90.16 and a 200 day moving average price of $82.85. The company has a market cap of $8.87 billion, a P/E ratio of 84.62, a PEG ratio of 1.59 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. On average, research analysts forecast that HealthEquity will post 2.27 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the transaction, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,536 shares of company stock worth $884,517. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HQY. GSA Capital Partners LLP purchased a new stake in shares of HealthEquity during the third quarter worth $638,000. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of HealthEquity by 36.7% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after buying an additional 226,563 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of HealthEquity by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock valued at $17,122,000 after buying an additional 48,009 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in HealthEquity by 29.4% in the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock worth $5,535,000 after buying an additional 14,573 shares during the last quarter. Finally, Diversify Wealth Management LLC bought a new position in HealthEquity during the second quarter valued at approximately $8,182,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.